Neuro-biological inferences into the depressive disorders of patients with chronic hepatitis C treated with interferon and ribavirin
© Hurezeanu et al; licensee BioMed Central Ltd. 2014
Published: 15 October 2014
This work is intended to establish a relation between two diseases, medical and psychiatric, both of them considered public health issues – chronic hepatitis C and depression. Interferon has been a great progress for the chronic hepatitis C patients’ therapy, but the treatment is encumbered by the occurrence of depression on 3-57% of patients. The purpose of this work is to assess the percent of the depressive disorder on chronic hepatitis C patients treated with interferon and ribavirin, as well as the monitoring of the related risk factors, upon depression occurrence and the evolution during anti-depressive treatment.
The retrospective study has been performed during the period of January 2011-January 2014 on a group of 64 patients with chronic hepatitis C, receiving combined antiviral treatment (interferon and ribavirin), aged between 25-64 years, observing the criteria of inclusion into treatment. The moment of psychiatric examination request has been recorded, 3.1% needing psychiatric examination before starting the therapy, 28.1% having symptoms which occurred during treatment.
The psychiatric examination has revealed as speeding causes of the depressive disorder the loss of social support for 39.5%, the biologic syndrome for 23%, and the loss of family support for 15.4%, and the depressive history for only 5.5%. The percent of the depressive patients after the starting moment of the antiviral therapy has emphasized the occurrence of the depressive disorder on 83% of patients during the first 0-12 weeks. The maximum incidence of cases has been recorded on patients with ages between 20-45 years. The cases distribution has been favorable to patients from urban area -15 cases, versus 3 cases from rural area.
The antiviral therapy for chronic hepatitis C has determined the occurrence of different levels of depression for 28.1% of the patients being studied. The anti-depressive treatment associated with the antiviral one has been efficient, decreasing the abandon rate of the antiviral therapy.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.